DK108589D0 - Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer - Google Patents

Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Info

Publication number
DK108589D0
DK108589D0 DK108589A DK108589A DK108589D0 DK 108589 D0 DK108589 D0 DK 108589D0 DK 108589 A DK108589 A DK 108589A DK 108589 A DK108589 A DK 108589A DK 108589 D0 DK108589 D0 DK 108589D0
Authority
DK
Denmark
Prior art keywords
antibodies
chimerary
humant
dna sequences
sequences coding
Prior art date
Application number
DK108589A
Other languages
English (en)
Other versions
DK108589A (da
Inventor
Dennis J Carlo
Gary Samuel David
Mary Jaqueline Johnson
Catherine Brautigam Beidler
James Richard Ludwig
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of DK108589D0 publication Critical patent/DK108589D0/da
Publication of DK108589A publication Critical patent/DK108589A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK108589A 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer DK108589A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16585688A 1988-03-09 1988-03-09
US27257788A 1988-11-17 1988-11-17

Publications (2)

Publication Number Publication Date
DK108589D0 true DK108589D0 (da) 1989-03-07
DK108589A DK108589A (da) 1989-09-22

Family

ID=26861757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK108589A DK108589A (da) 1988-03-09 1989-03-07 Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer

Country Status (5)

Country Link
EP (1) EP0332424A3 (da)
JP (1) JPH029371A (da)
AU (1) AU618990B2 (da)
DK (1) DK108589A (da)
IL (1) IL89489A0 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5081235A (en) * 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
CA2044590A1 (en) * 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1993017106A1 (en) * 1992-02-19 1993-09-02 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6380979B1 (en) * 1996-07-02 2002-04-30 Matsushita Electric Industrial Co., Ltd. Scanning line converting circuit and interpolation coefficient generating circuit
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
CA2419148C (en) 2000-05-16 2011-07-12 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
PT2305301E (pt) 2002-07-19 2015-04-21 Beth Israel Hospital Métodos de tratamento de pré-eclâmpsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
JP2007535895A (ja) 2003-05-01 2007-12-13 イムクローン システムズ インコーポレイティド ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体
CN103007279B (zh) 2004-03-19 2017-01-11 英克隆有限责任公司 人抗表皮生长因子受体抗体
WO2006021893A2 (en) 2004-08-26 2006-03-02 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
DE602005024850D1 (de) 2004-09-24 2010-12-30 Beth Israel Hospital Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
SI1819358T1 (sl) 2004-11-18 2014-10-30 Imclone Llc Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
US7598043B2 (en) 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (ko) 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
MX346172B (es) 2007-08-29 2017-03-10 Sanofi - Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
EP2324060B1 (en) 2008-09-07 2015-07-22 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
JP5925678B2 (ja) 2009-08-18 2016-05-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 増殖性および病原性疾患の治療のための方法および組成物
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
SG10201407519TA (en) * 2009-11-19 2015-01-29 Univ Singapore Method For Producing T Cell Receptor-Like Monoclonal Antibodies And Uses Thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
PT2663579T (pt) 2011-01-14 2017-07-28 Univ California Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização
PL3235508T3 (pl) 2011-03-16 2021-07-12 Sanofi Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
DE202014008375U1 (de) 2014-10-18 2015-10-21 Reinz-Dichtungs-Gmbh Seperatorplatte und elektrochemisches System
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
TWI808963B (zh) 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN113891729A (zh) 2019-05-24 2022-01-04 赛诺菲 治疗系统性硬化症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates

Also Published As

Publication number Publication date
AU3107289A (en) 1989-09-14
IL89489A0 (en) 1989-09-10
AU618990B2 (en) 1992-01-16
JPH029371A (ja) 1990-01-12
DK108589A (da) 1989-09-22
EP0332424A2 (en) 1989-09-13
EP0332424A3 (en) 1991-07-03

Similar Documents

Publication Publication Date Title
DK108589D0 (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DK108189A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen og metal-chelater samt dna-sekvenser, der koder for saadanne antistoffer
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE68911113D1 (de) Kodiereinrichtung.
NO891818D0 (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
DE68914138D1 (de) Substrat-gebundene oligonukleotide.
DE3879452D1 (de) Chimaere antikoerper.
DK38989D0 (da) Dna-sekvens
NO892416D0 (no) Polyamider.
NO892294D0 (no) Polypeptidforbindelser.
NO881384D0 (no) Peptider.
DE58908164D1 (de) Füllelement.
DE68922166D1 (de) Chiffrierverfahren mit nachträglicher Quellenkodierung.
NO885108L (no) Peptider.
DE68916020D1 (de) Auftragemethode.
FI861691A (fi) En ny tumoerassocierad antigen.
DE3482813D1 (de) Adult t-zell-leukemiavirus-antigenpeptid.
DE68908528D1 (de) Testmethode.
FI893450A (fi) Modifierade proteiner.
DK324287D0 (da) Antistof mod koensspecifikt antigen
DK108489A (da) Chimere antistoffer rettet mod metal-chelater af edta-derivater, samt dna-sekvenser, der koder for saadanne antistoffer
DK578189D0 (da) Dna-sekvens
DK448687D0 (da) Dna, der koder for et virusantigen
ATE87031T1 (de) Chimaere antikoerper.
ITRM920716A0 (it) Composto proteico e sequenze nucleotidiche codificanti per esso.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment